Sign In
Buy MRNA
$49.06
+3.42 (+7.49%)
At Close: Jun 03, 2026
Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates
07:00am, Friday, 01'st Aug 2025
Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 projected revenue range to $1.5 to $2.2 billion, reflecting a $300 million reducti
President Trump demands drugmakers slash prices within 60 days
06:54am, Friday, 01'st Aug 2025
CNBC's Joe Kernen reports on the latest news.
UK Court of Appeal Confirms Moderna's EP'949 Patent is Valid and Infringed by Pfizer/BioNTech
06:00am, Friday, 01'st Aug 2025
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna's EP'949 patent. This decision affirms the
Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win
05:59am, Friday, 01'st Aug 2025
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
Moderna Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
04:37am, Friday, 01'st Aug 2025
Moderna, Inc. MRNA will release earnings results for the second quarter, after the closing bell on Friday, Aug. 1.
More than 800 Moderna employees will lose their jobs this year as costs are slashed
09:14am, Thursday, 31'st Jul 2025
In a note to employees on Thursday, Moderna Inc. said it was laying off about 10% of its global workforce as part of the biotechnology company's plan to cut costs by $1.5 billion over the next couple
Moderna plans to lay off 10% of workforce to cut costs
07:34am, Thursday, 31'st Jul 2025
Moderna plans to trim roughly 10% of its global workforce by the end of the year to cut costs amid declining sales of its COVID-19 vaccines, the company said on Thursday.
Moderna to slash 10% of workforce as biotech cuts costs, Covid shot sales slow
07:15am, Thursday, 31'st Jul 2025
Moderna said it plans to slash roughly 10% of its global workforce by the end of the year, as Covid shot sales continue to dwindle and the company grapples with uncertainty in the vaccine market. In
Pandemic darlings Moderna, BioNTech are now on two different paths
07:00am, Thursday, 31'st Jul 2025
Covid-19 vaccine makers Moderna and BioNTech became household names almost overnight. Moderna and BioNTech have spent their Covid vaccine windfalls differently, with Moderna investing in its own mRNA
Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
04:05pm, Wednesday, 30'th Jul 2025
CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for the updated formulation of the C
Curious about Moderna (MRNA) Q2 Performance? Explore Wall Street Estimates for Key Metrics
10:16am, Tuesday, 29'th Jul 2025
Evaluate the expected performance of Moderna (MRNA) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for
Moderna to Report Q2 Earnings: Is a Beat in Store for the Stock?
09:31am, Tuesday, 29'th Jul 2025
MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline milestones.
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
11:31am, Monday, 28'th Jul 2025
Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.
Moderna Announces Data to be Presented at ESMO Congress 2025
07:00am, Monday, 28'th Jul 2025
CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2
Down 74% Over the Past Year, Is Moderna Stock a Buy?
03:55am, Saturday, 26'th Jul 2025
In the short term, Moderna (MRNA 0.41%) looks like a bad bet. It's coming off of the momentum of its COVID-19 vaccine, and doesn't have a lot of new ammo ready yet to expand in new directions.
